You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MK-2206

Showing 1 - 25 of 878
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Malignant Solid Tumor, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7 Trial in New Brunswick

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Jan 25, 2023

Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States

Completed
Has Results
  • Endometrial Adenocarcinoma
  • +4 more
  • Akt Inhibitor MK2206
  • Laboratory Biomarker Analysis
  • Boston, Massachusetts
  • +6 more
Jan 13, 2022

Lung Cancer Trial in New Haven, Houston (Erlotinib, AZD6244, MK-2206)

Completed
Has Results
  • Lung Cancer
  • New Haven, Connecticut
  • +1 more
Dec 14, 2021

NSCLC, Carcinoma, Small Cell Lung, Carcinoma, Thymic Trial run by the National Cancer Institute (NCI) (AZD6244, MK-2206,

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022

Breast Cancer Trial in Saint Louis (Diagnostic Imaging ( 6a-[18F]fluoro-17ß-estradiol (FES)))

Withdrawn
  • Breast Cancer
  • Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))
  • Saint Louis, Missouri
    Mallinckrodt Institute of Radiology
Oct 21, 2021

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +35 more
  • Akt inhibitor MK2206
  • laboratory biomarker analysis
  • Houston, Texas
    M D Anderson Cancer Center
Oct 14, 2020

Metastatic Kidney Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7 Trial in United States (Akt

Terminated
Has Results
  • Metastatic Kidney Carcinoma
  • +3 more
  • Akt Inhibitor MK2206
  • +2 more
  • Beverly Hills, California
  • +7 more
Sep 25, 2019

Breast Tumors, Breast Cancer, Breast Tumors Trial in United States (Standard Therapy, AMG 386 with or without Trastuzumab, AMG

Recruiting
  • Breast Neoplasms
  • +10 more
  • Standard Therapy
  • +32 more
  • Birmingham, Alabama
  • +35 more
Nov 17, 2022

Respiratory Syncytial Virus Infection Trial in Worldwide (MK-1654, Placebo)

Recruiting
  • Respiratory Syncytial Virus Infection
  • MK-1654
  • Placebo
  • Dothan, Alabama
  • +149 more
Mar 31, 2022

Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer Trial in United States (Akt Inhibitor MK2206,

Completed
Has Results
  • Recurrent Breast Carcinoma
  • +3 more
  • Akt Inhibitor MK2206
  • +2 more
  • Boston, Massachusetts
  • +4 more
Nov 28, 2018

HIV Infection Trial in Worldwide (DOR/ISL)

Active, not recruiting
  • HIV Infection
  • Washington, District of Columbia
  • +77 more
Oct 7, 2021

Locally Advanced or Metastatic Solid Tumors Trial (MK-2206, AZD6244)

Completed
Has Results
  • Locally Advanced or Metastatic Solid Tumors
  • (no location specified)
Nov 3, 2017

Breast Tumors Trial in Worldwide (pembrolizumab, paclitaxel, nab-paclitaxel)

Recruiting
  • Breast Neoplasms
  • pembrolizumab
  • +6 more
  • Tucson, Arizona
  • +188 more
Aug 11, 2022

Lung Tumors, NSCLC Trial in Worldwide (biological, drug, radiation)

Recruiting
  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Pembrolizumab
  • +9 more
  • Mobile, Alabama
  • +194 more
Aug 18, 2022

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic

Completed
Has Results
  • Adult Acute Megakaryoblastic Leukemia (M7)
  • +14 more
  • Akt inhibitor MK2206
  • laboratory biomarker analysis
  • Houston, Texas
  • +1 more
Jul 27, 2018

Estrogen Receptor Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma Trial in Saint Louis (Akt Inhibitor MK2206,

Completed
  • Estrogen Receptor Positive
  • +3 more
  • Akt Inhibitor MK2206
  • +3 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 20, 2018

Clinical, Histological and Prognostic Forms of Adenocarcinoma of

Active, not recruiting
  • Anal Adenocarcinoma
    • Paris, France
    • +1 more
    Nov 7, 2022

    NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +4 more
    • MK-2870
    • +2 more
    • (no location specified)
    Sep 15, 2023

    Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma Trial in United States (drug, other, procedure)

    Terminated
    Has Results
    • Estrogen Receptor Positive
    • +7 more
    • Akt Inhibitor MK2206
    • +6 more
    • Scottsdale, Arizona
    • +7 more
    Apr 6, 2018

    Endometrial Cancer Trial (MK-2870, Doxorubicin, Paclitaxel)

    Not yet recruiting
    • Endometrial Cancer
    • MK-2870
    • +2 more
    • (no location specified)
    Nov 10, 2023

    Schizophrenia Trial (MK-8189, Moxifloxacin, Placebo)

    Not yet recruiting
    • Schizophrenia
    • (no location specified)
    May 30, 2023

    NSCLC, Renal Cell Carcinoma, Melanoma Trial (Pembrolizumab co-formulated with hyaluronidase, Pembrolizumab)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Pembrolizumab co-formulated with hyaluronidase
    • Pembrolizumab
    • (no location specified)
    Oct 19, 2023

    Ulcerative Colitis Trial (IV MK-7240, IV Placebo, SC MK-7240)

    Not yet recruiting
    • Ulcerative Colitis
    • IV MK-7240
    • +3 more
    • (no location specified)
    Sep 27, 2023

    Schizophrenia Trial (MK-5720, Placebo)

    Not yet recruiting
    • Schizophrenia
    • (no location specified)
    Jul 24, 2023

    Tumors Trial in Worldwide (MK-4830, Pembrolizumab, Carboplatin)

    Recruiting
    • Neoplasms
    • San Francisco, California
    • +31 more
    Dec 23, 2022